This article is more than 5 years old. Information may no longer be current.
Annexon Biosciences closes $75 million funding round
Click Here to Manage Email Alerts
Annexon Biosciences has closed a $75 million Series C round of financing, which will be used to develop multiple product candidates, including an antigen-binding fragment candidate for use in ophthalmic settings, the company announced in a press release.
Led by Bain Capital Life Sciences, the financing included participation from Surveyor Capital and Adage Capital Partners, as well as existing investors NEA, Blackstone Life Sciences, Novartis Venture Fund and Satter Investment Management.
“We have made great strides in building a portfolio of product candidates across multiple indications over the past 2 years,” Doug Love, CEO and president of Annexon, said in the release. “Proceeds from this financing will fund our lead programs in antibody-mediated autoimmune, ophthalmic and neurodegenerative indications through several clinical stages, including completion of proof-of-concept trials.”
The company’s ophthalmic drug candidate, ANX007, is currently in phase 1b proof-of-principle studies.